ArticleHeliyon2023
Fibrinogen-to-albumin ratios are related to mortality in patients with secondary malignant neoplasm of bone and bone marrow.
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Proposing an Optimized Prediction Model for Pancreatic Cancer Based on Mendelian Randomization Analysis of Fibrinogen Levels and Urinary Protein Excretion Rate.Clinical Medicine Insights. Oncology · 2026Article
- L-shaped association between fibrinogen to serum albumin ratio and all-cause mortality among critically ill children: a retrospective cohort study.BMC pediatrics · 2025Article
- Article
- Fibrinogen and tumors.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic inflammation has long been considered to be one of the mechanisms in the development and progression of secondary malignant neoplasm of bone and bone marrow (BM). Fibrinogen-to-albumin ratio (FAR) has been demonstrated to be vital to the poor prognosis of lots of disease such as tumor and coronary heart disease. This study aimed to determine whether FAR could be used as an independent risk prognostic factor in patients with BM. Methods: Firstly, the baseline data of patients with BM, who met our inclusion/exclusion criteria, were extracted and analyzed from MIMIC-III database. The association between FAR and endpoints was analyzed using a Cox proportional hazards regression model and a propensity score matched analysis. Results: The univariate analysis revealed that for the 30-day mortality, the HR (95% CI) in the FAR ≥99.5group was 1.47 (1.15,1.91). After adjusting various factors, FAR ≥99.5 was found to be an independent significant risk factor for death in patients with BM (HR = 1.11, 95% CI: 1.01-1.42). Similarly, for the one-year mortality, HR (95% CI) in the FAR ≥99.5 group was 1.51 (1.11, 2.06). Conclusion: It has been found that FAR provides independent prognostic information for mortality among patients with secondary malignant neoplasms of the bone and bone marrow.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.